Category Archives: oud

The Power Of Quantifying Market Expectations For McDonald’s And Williams Companies

” It’s difficult to make predictions, especially about the future. ” This quote has been repeated so many times that no one quite knows who said it first. Perhaps it was baseball player Yogi Berra. Or humorist Mark Twain. Or Danish physicist Niels Bohr. The point is, this quote has become a part of our cultural fabric, and it has done so because it expresses a simple and fundamental truth. Accurately forecasting what’s going to happen in the future is incredibly difficult, almost impossible. Few areas illustrate this difficulty more profoundly than financial markets, where analyst projections of earnings are regularly off by 10+% . Sometimes, even the most well recognized experts make shockingly bad predictions . No one truly knows (legally) what the market is going to do next, and the risk involved in that uncertainty is what creates the potential for significant returns. The Alternative To Making Predictions Of course, those returns are only available to those that participate in the stock market, and participating in the market implies some sort of prediction about the future. Even if you just buy a broad-based index fund, you’re predicting the broader market will go up. Otherwise, why make that (or any) investment? However, there’s a better way to invest. Instead of making your own prediction about the future, you can analyze the market’s prediction by quantifying the cash flow expectations baked into the market’s valuation of a stock. Then, you can make a more objective judgment about whether or not those expectations are realistic. This method, termed ” Expectations Investing ” by Alfred Rappaport and Michael Mauboussin in their book of the same name, can be incredibly effective. It’s effective because it removes the need to make precise predictions about the future. By quantifying market expectations across thousands of stock as we do, it’s easy to find pockets of irrationality and identify companies that are over or undervalued. How To Quantify Market Expectations There are a couple of methods we use to quantify market expectations. One of the simplest is to calculate a company’s economic book value , or the no-growth value of the business based on the perpetuity value of its current cash flows. This value can be calculated by dividing a company’s LTM after-tax profit ( NOPAT ) by its weighted average cost of capital ( WACC ), and then adjusting for non-operating assets and liabilities. Figure 1: Why We Recommended McDonald’s Click to enlarge Sources: New Constructs, LLC and company filings. The ratio of a company’s stock price to its economic book value per share (PEBV) sends a clear message about market expectations for the stock and can be a very powerful tool for investors. Figure 1 shows how PEBV influenced our decision to recommend McDonald’s (NYSE: MCD ) shares to investors in late 2012. Shares at that time were trading at a PEBV of 0.82, an unprecedented discount for a company with MCD’s track record of growth and profitability. The market’s valuation suggested that MCD’s NOPAT would permanently decline 18% and never recover. Those expectations seemed overly pessimistic to us. As it turned out, MCD did end up struggling significantly after our call. Increased competition from fast casual restaurants like Chipotle (NYSE: CMG ) and Panera (NASDAQ: PNRA ) that appealed to health-conscious diners compressed MCD’s margins and sent its sales slumping. Despite its struggles, however, things never got quite as bad for MCD as the market predicted. Between 2012 and 2015, NOPAT fell by only 16%, not the 18% projected by the stock price, and recent signs of a recovery have sent shares soaring to all-time highs. Figure 2 shows how MCD has delivered significant returns to investors since we made our prediction despite lackluster financial results. Figure 2: Disappointing Profits No Obstacle To Shareholder Returns Click to enlarge Sources: New Constructs, LLC and company filings. Though MCD’s poor results caused it to miss out on the bull run of 2013-2014, its surge over the past twelve months has it at a 51% gain since our initial call, outperforming the S&P 500 (NYSEARCA: SPY ) on a capital gains basis while also yielding a higher dividend. We didn’t know exactly how McDonald’s was going to perform when we made the prediction in 2012. We simply knew that the expectations baked into the market’s valuation were so pessimistic that even if the company’s profits significantly declined, as they did, investors could still earn healthy returns. Delayed Gratification As Figure 2 shows, basing investment decisions off a quantification of market expectations doesn’t always deliver immediate results. In the case of MCD, it took nearly three years for our call to come to fruition. Short-term sector trends and market forces can allow a company to stay valued at irrational levels for quite some time especially when we know that very few people practice Expectations Investing these days. Roughly three years ago, we warned investors to stay away from Williams Companies (NYSE: WMB ), calling it an example of the “sector trap.” Analysts excited about the company’s exposure to the rapidly growing natural gas sector were pumping up the stock, ignoring its low and declining return on invested capital ( ROIC ), significant write-downs indicating poor capital allocation, and the high expectations implied by its stock price. Specifically, our discounted cash flow model showed that the company would need to grow NOPAT by 13% compounded annually for 15 years to justify its price at the time of ~$37/share. Those expectations seemed to be clearly unrealistic given the company’s 7% compounded annual NOPAT growth over the previous decade and a half. For a time, WMB continued to gain in value despite the disconnect between its current cash flows and the cash flows implied by the stock’s valuation. As recently as mid-2015, the stock was up nearly 60% from our original call. However, as Figure 3 shows, WMB crashed hard when the market turned more volatile. It now has fallen nearly 60% from our original call, and it has significantly underperformed the S&P 500, the S&P Energy ETF (XEP), and peers Spectra Energy (NYSE: SEP ) and Enterprise Products Partners (NYSE: EPD ). Figure 3: Short-Term Gains, Long-Term Declines Click to enlarge Source: Google Finance Stocks with overly high expectations embedded in their prices can still perform well in the short-term, but they tend to face a reckoning eventually. Stocks Due For A Correction Roughly a year ago, we put engine manufacturer Briggs & Stratton (NYSE: BGG ) in the Danger Zone . Back then we argued that BGG’s history of value-destroying acquisitions, significant write-downs, and declining profits made it unlikely that the company would hit the high expectations set by the market. Specifically, our model showed that the company needed to grow NOPAT by 10% compounded annually for 17 years to justify its price at the time of ~$20/share. BGG actually did manage to meet this goal in year 1, growing NOPAT by 14% in 2015. However, we think this growth rate is unsustainable, as the company’s ROIC remains mired below 5%. Moreover, the company keeps spending money it doesn’t have on acquisitions, dividends, and buybacks, so it now sits with almost no excess cash and $660 million (68% of market cap) in combined debt and underfunded pension liabilities. Despite the balance sheet concerns, the market only seemed to pay attention to the GAAP earnings growth, and BGG is up 13.8% since our call. At its new price of ~$23/share, the market expects 10% compounded annual NOPAT growth for the next 11 years . Despite one good year in 2015, there’s no reason to suspect that level of growth is sustainable for BGG. High market expectations mean this stock should drop hard the moment growth slows down. On the other side of the coin, we still believe last year’s long pick Fluor Corporation (NYSE: FLR ) has significant upside. Despite slumping commodities prices affecting its oil, gas, and mining businesses, FLR still managed a 21% ROIC in 2015 and finished the year with a larger backlog than it had at the end of 2014. Investors only saw the downside though, and they sent FLR down 11% Due to this decline, the market continues to assign FLR a low PEBV of 0.9, just as it did last March when we made our original call. Given the recent rebound in commodities, we don’t think a permanent 10% decline in NOPAT from these already low levels seems likely. Strong profitability and low market expectations lead us to believe an investment in FLR will pay off sooner or later. Disclosure: David Trainer and Sam McBride receive no compensation to write about any specific stock, sector, style, or theme. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

BioMarin Gene Therapy For Hemophilia Scores In Trial; Stock Jumps

Rare-disease specialist BioMarin Pharmaceutical ( BMRN ) was trading up sharply Wednesday after it reported strong early-stage trial results for its gene therapy for hemophilia. BioMarin delivered a single dose of its candidate BMN 270 to eight patients with severe hemophilia A — the most common variety of the disease, which makes sufferers’ blood unable to clot. Six of those were on the highest dose, and all of those “improved from severe to either moderate, mild or normal range in terms of factor levels based on World Federation of Hemophilia criteria,” according to BioMarin’s press release. BioMarin is already preparing a large phase-three trial of BMN 270 in hopes of gaining FDA approval as quickly as possible. If successful, it could be a paradigm shift in hemophilia treatment. Currently, the only treatment is regular infusions of natural or recombinant blood-derived products to replace the missing clotting factors. A gene therapy, by attacking the disease’s origin in a defective X chromosome, could provide improvement for much longer, although since BioMarin’s trial only followed up after 16 weeks, it’s unclear just how long it is effective. Currently, hemophilia treatment is dominated by Baxalta ( BXLT ) — which is in the process of being acquired by Shire ( SHPG ) — and Biogen ( BIIB ). Both companies are working on their own gene therapies. Pfizer ( PFE ) holds the dominant position in the smaller hemophilia B market. RBC Capital Markets estimates that the hemophilia A market alone is about $4 billion a year. BioMarin stock was up 5% in early trading on the stock market today , near 90.50, and touched a three-month intraday high. Since last summer, the stock has been hit not only by the larger biotech sell-off, but also by the FDA’s rejection in January of its muscular dystrophy drug Kyndrisa, as well as mixed late-stage trial results last month on a treatment for another rare disease, called phenylketonuria. Currently its IBD Relative Strength Rating is a dismal 15, meaning the stock has performed among the lowest 15% of all stocks over the past 12 months. “While the data presented today were small numbers and of relatively limited follow-up … the data were encouraging (though looks like significant variability from patient to patient) and (1) suggest a path forward for BMN 270 in hemophilia A (and potentially for hemo A gene therapy in general) and (2) set a reasonably high bar for competition that will follow,” wrote Evercore ISI analyst Mark Schoenebaum in an email to clients. Image provided by Shutterstock .

Yahoo Earnings Beat Despite Ongoing Challenges; Acquisition Near?

Yahoo ( YHOO ) stock opened higher Wednesday after the company late Tuesday assured investors it’s working diligently to find a buyer for its core, and perhaps other, businesses. Executives didn’t give any specifics, however, and its Q2 revenue outlook fell short of Wall Street estimates, as the Web company continues to cut costs. CFO Ken Goldman said the company’s headcount, including contractors, was down to 9,200, which it said is down 42% from the start of 2012. RBC Capital Markets analyst Mark Mahaney hiked his price target on Yahoo stock to 38 from 33, citing the rise of its Asian assets and his sum-of-its-parts analysis of the company. But he maintained his market perform rating on Yahoo stock. Most analysts maintained the equivalent of neutral ratings and maintained their price targets. Yahoo stock was up 2.5%, above 37, in early trading in the stock market today . “We are moving forward at the fastest possible pace,” Yahoo CEO Marissa Mayer said on the company’s earnings conference call last Tuesday. Verizon Communications ( VZ ), which bought AOL last year for $4.4 billion, is widely considered to be the front-runner for Yahoo’s core business. It’s uncertain what Yahoo will do with its 15% stake in China e-commerce leader Alibaba ( BABA ) or its big stake in Yahoo Japan. Late Tuesday, the Wall Street Journal reported that besides Verizon, bidders include U.K. publisher Daily Mail, buyout firm TPG and an investor group that included Bain Capital, Vista Equity Partners and former Yahoo interim CEO Ross Levinsohn. Mayer, then a top executive with Google (now part of Alphabet ( GOOGL )), was chosen over Levinsohn and others for the top spot at Yahoo in 2012. Private-equity firms, Silver Lake and Advent International also expressed interest in bidding, the WSJ said. Yahoo continues to attract more than 1 billion unique visitors a month to its online properties, long among the leaders on that score, but it’s spent a decade failing to spark much, if any, revenue growth. Yahoo Revenue Declines Accelerating For Q1, Yahoo said its earnings per share minus items fell 47% to 8 cents from 15 cents in Q1 2015, but analysts polled by Thomson Reuters had expected just 7 cents. Revenue fell 11% to $1.09 billion, just above the $1.08 billion that analysts had expected. For Q2, the company forecast revenue of $1.05 billion to $1.09 billion, down 14% at the midpoint and lagging consensus views of $1.102 billion. Facebook ( FB ) and Alphabet continue to gain in mobile and digital advertising at the expense of Yahoo and others. Cowen analyst John Blackledge, in a research note, pointed out the company posted a deceleration in mobile revenue growth and in growth for what its calls MAVENs, referring to the higher-growth areas of mobile, social, video and native advertising. He maintained a 32 price target on Yahoo stock. Yahoo did say MAVENs accounted for 38% of its total traffic-driven revenue, up from 33% in Q1 2015. William Blair analyst Ralph Schackart kept his market perform rating, citing “Yahoo’s weak core business fundamentals,” in a research note. “Yahoo’s search business continues to experience headwinds from declining desktop traffic, with paid clicks down 21% year over year in the first quarter after being down 10% last quarter,” Schackart wrote. “Further, search partnerships and increased affiliate traffic have caused traffic acquisition costs to grow at a faster rate than gross revenue, resulting in net search revenue declining 21% year over year in the first quarter.”